KCA Logo 

The Kidney Cancer Association is pleased to announce applications for both its Young Investigator Awards (YIAs) and Advanced Discovery Awards (ADAs) will open March 18, 2020. 

A total of $1.3 million in funding will be available: 

· Four $75,000 YIAs 

· Two $500,000 ADAs 

Applications for Letters of Intent (LOIs) for the ADA awards will be accepted March 18 to May 20. Invitation for Full Proposals for ADA awards will be sent on June 10 and the deadline for Full Proposals is August 5. Full Proposals for YIA awards will be accepted March 18 to August 5. LOIs for YIA awards are not required. Recipients will be announced in fall 2020.

The priority research areas that emerged as a result of the KCA’s Think Tank: Coalition for a Cure, held last fall in conjunction with the 18th International Kidney Cancer Symposium, included cure or durable therapeutic response, improved screening and surveillance, neoadjuvant and adjuvant treatment strategies, and non-clear cell renal cell carcinoma. 

YIAs encourage promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer. ADAs, which were established in 2019, promote collaboration between established clinicians and scientists to propose new, impactful research.

All grant proposals will be evaluated by an independent panel of reviewers, who are recognized experts in the field. They will conduct a blinded, scored review of all applications received.

For questions, please contact sshirley@kidneycancer.org. 

The Kidney Cancer Association funds four research awards annually to provide grants to promising young investigators to encourage and promote quality research in kidney cancer. The hope is that by supporting investigators that are early in their career, with the support and guidance of appropriate mentorship, the awardees will continue to develop their research interests in kidney cancer, which will lead to significant advances in the field. Proposals should be projects that can be realistically accomplished in one year and will provide sufficient preliminary data to lead to potential further funding through other granting mechanisms.  

All application materials will be submitted electronically in PDF format.

Instructions for Submission:

o First attachment - Applicants must upload relevant biosketch(s) in NIH format. This must be a separate document.

o Second attachment - Applicants must upload relevant biosketch(s) for their mentor in NIH format. This must be a separate document.

o Third attachment - Applicants must upload their mentor's letter/plan. This must be a separate document.

o Fourth attachment - Applicants must submit a 4 page, single spaced, Arial font 11 document in PDF format.  

o All relevant graphs, tables, and figures must be included within the 4 pages.  

o The document should elaborate on the background and work done to date.  

o Specific Aims must be clearly stated and the methodology to accomplish the specific aims detailed, including alternative methods should the primary experiments not work as planned.

o The potential impact on the care of patients with kidney cancer must be stated.

o Timelines and actionable goals of the research plan should be highlighted.

o Fifth attachment - Applicants must submit a 4 page, single spaced, Arial font 11 document in PDF format, same as above, but all information in this attachment should be redacted, and not include any names of collaborators, mentors, or current/previous institutions. May not be on institutional letterhead.

o Sixth attachment – Applicants must submit a budget and a justification for said budget.

o Seventh attachment - Applicants should cite relevant literature and include references. Additionally, they should indicate whether or not their research proposal is under consideration by other granting mechanisms. 

Two annual $500,000 grants will target the early detection and innovative treatments of kidney cancer. The purpose of establishing this Advanced Discovery Award (ADA) is to promote the collaboration between a clinician including a urologic oncologist, medical oncologist or radiation oncologist and a predominately research based collaborator (Ph.D., M. D., D. O.) to propose new research that will make an immediate impact in the field of kidney cancer.

All application materials will be submitted electronically in PDF format.

Submission guidelines:

 Applicants must submit a two page, single spaced, Arial 11 font proposal in PDF format for review. The proposal should highlight the background, relevance, and the potential impact of the research proposed. Hypotheses or specific aims to be tested should be clearly stated and a brief review of the methodology should be included. A statement of how this research will advance the field regarding the potential impact on patient care must be included. Relevant references should also be cited in the document. 

A full version and redacted version are required.  All information in the redacted file must be redacted, and not include any names of collaborators, mentors, or current/previous institutions. May not be on institutional letterhead. 

 Accompanying the Letter of Intent should be the contact information and biosketches of the collaborative researchers as well as a one paragraph personal statement from each of the researchers regarding their background and commitment to research in the field of kidney cancer. Relevant IRB approved protocols for use of human or animal specimens in the proposed research should also be included. Supporting documentation from a pharmaceutical company should be included if a drug is proposed in the research plan. Finally, a letter of support from each applicant’s department or division chairman should accompany the letter of intent.